The U.S. Department of Health and Human Services (HHS) has disputed Merck & Co. Inc.’s interpretation of the Inflation Reduction Act’s Medicare drug price-negotiation program. HHS claims the pharmaceutical company’s lawsuit is replete with “misunderstandings” of the law, as per a statement made during an ongoing D.C. federal court case.
Merck mounted a legal challenge against the Inflation Reduction Act’s provisions for Medicare drug price negotiations. In response, the HHS, under the defense of its leadership and legal counsel, sought a summary judgment, aiming to rebuff Merck’s legal assertions on the grounds of misinterpretation.
Details of these “misunderstandings” have not been elaborated on at this stage, however they are presumably centred around the specifics of Medicare drug pricing under the Inflation Reduction Act.
It is evident that these disagreements underscore the contentious nature of drug pricing laws in the U.S., particularly as they concern large pharmaceutical corporations like Merck.
For more on this ongoing case, visit Law360.